Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
 
Sign in
Join now
Published in COVID-19 and
1 other channel

Journal Scan / Research · March 03, 2022

The 6-Month Humoral Response to the BNT162b2 mRNA COVID-19 Vaccine in People With MS Treated With Natalizumab

Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Michael Kornberg MD, PhD

Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab
Neurol. Sci. 2022 Feb 16;[EPub Ahead of Print], M Altieri, R Capuano, M Conte, G Donnarumma, E Grimaldi, N Coppola, M Galdiero, A d'Ambrosio, G Tedeschi, A Gallo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated